<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2311">
  <stage>Registered</stage>
  <submitdate>31/03/2009</submitdate>
  <approvaldate>31/03/2009</approvaldate>
  <nctid>NCT00874523</nctid>
  <trial_identification>
    <studytitle>Raltegravir and Atazanavir Dosing Strategy Study</studytitle>
    <scientifictitle>A Randomised, Open-label, Cross-over Study to Examine the Pharmacokinetics and Short-term Safety and Efficacy of Two Dosing Strategies of Raltegravir Plus Atazanavir in HIV-infected Patients</scientifictitle>
    <utrn />
    <trialacronym>SPARTA</trialacronym>
    <secondaryid>SPARTA</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>HIV Infection</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Acquired immune deficiency syndrome (AIDS / HIV)</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - atazanavir plus raltegravir
Treatment: drugs - atazanavir plus raltegravir

Active Comparator: Arm A - 

Active Comparator: Arm B - 


Treatment: drugs: atazanavir plus raltegravir
atazanavir 300 mg + raltegravir 400 mg twice daily for 4 weeks then atazanavir 300 mg + ritonavir 100 mg + raltegravir 800 mg once daily for 4 weeks

Treatment: drugs: atazanavir plus raltegravir
atazanavir 300 mg + ritonavir 100 mg + raltegravir 800 mg once daily for 4 weeks then atazanavir 300 mg + raltegravir 400 mg twice daily for 4 weeks

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>comparison of the mean steady-state atazanavir trough plasma concentrations for once (C24) and twice (C12) daily dosing strategies</outcome>
      <timepoint>4 and 8 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>comparison of mean steady-state raltegravir trough plasma concentrations for once (C24) and twice (C12) daily dosing</outcome>
      <timepoint>4 and 8 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>comparison of steady-state pharmacokinetic profiles of once and twice-daily atazanavir</outcome>
      <timepoint>4 and 8 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>comparison of the steady-state pharmacokinetic profiles of once and twice-daily raltegravir</outcome>
      <timepoint>4 and 8 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>change from baseline in fasting lipid and glycaemic parameters</outcome>
      <timepoint>weeks 4 and 8 and overall</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>change from baseline in CD4+ T-lymphocyte count</outcome>
      <timepoint>weeks 4 and 8 and overall</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>change from baseline in HIV-RNA</outcome>
      <timepoint>weeks 4 and 8 and overall</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>all adverse events attributable to study treatment</outcome>
      <timepoint>week 8</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>all serious, grade 3 or 4 clinical adverse events, and any adverse event leading to premature cessation of study treatment</outcome>
      <timepoint>week 8</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  aged = 18 years with laboratory evidence of HIV-1 infection

          -  currently receiving 3 or more unchanged antiretroviral agents including atazanavir
             (with or without ritonavir boosting) for at least 24 weeks prior to study entry

          -  plasma HIV RNA less than 50 copies/mL for at least 24 weeks prior to study entry

          -  provide written, informed consent.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Exclusion Criteria :

          -  prior clinical/virological failure on a PI-containing regimen

          -  no clinical history of primary HIV-1 protease mutations identified in local baseline
             genotypic analysis of HIV with interpretation using current IAS-USA Drug Resistance
             Mutations in HIV-1

          -  women: pregnant, breastfeeding, or not willing to use adequate contraception
             (including barrier contraception) if of child-bearing potential

          -  laboratory abnormalities at screening:

               -  absolute neutrophil count (ANC) &lt; 750 cells/mL

               -  haemoglobin less than 8.5 g/dL

               -  platelet count less than 50 000 cells/mL

               -  AST, ALT &gt; 5 times the upper limit of normal

               -  serum bilirubin &gt; 5 times the upper limit of normal

          -  chronic active hepatitis B infection defined by presence of serum viral hepatitis B
             surface antigen (HBsAg) or HBV DNA-positive

          -  any malabsorption syndrome likely to affect drug absorption

          -  concurrent therapy with human growth hormone or other immunomodulatory agents

          -  concomitant medication contraindicated for use with either atazanavir or raltegravir
             therapy

          -  any inter-current illness requiring hospitalisation

          -  current excessive alcohol or illicit substance use

          -  unlikely to be able to remain in follow-up for the protocol-defined period.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/07/2009</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>26</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/07/2011</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <hospital>Holdsworth House Medical Practice - Sydney</hospital>
    <hospital>St Vincent's Hospital - Sydney</hospital>
    <postcode>2010 - Sydney</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Kirby Institute</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>To compare the steady-state pharmacokinetics and short-term efficacy and safety of two dosing
      strategies of raltegravir and atazanavir in virologically suppressed HIV-infected adults
      receiving atazanavir-containing combination antiretroviral therapy.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00874523</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>David A Cooper, MD DSc</name>
      <address>Kirby Institute/UNSW</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>